REG - IXICO plc - IXICO Updates AI Neuroimaging Platform

IXICOAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260512:nRSL7986Da&default-theme=true

RNS Number : 7986D  IXICO plc  12 May 2026

IXICO plc

("IXICO", the "Company" or the "Group")

 

IXICO RELEASES LATEST VERSION OF AI-DRIVEN NEUROIMAGING TECHNOLOGY PLATFORM

 

IXI™ (Version 10) advances data processing speed and volume

 

 

12 May 2026, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in
neuroscience imaging and biomarker analytics, using its AI-driven platform to
help advance drug development in neurological disorders, today announced the
latest version release (v.10) of IXI™, IXICO's proprietary AI enabled
neuroimaging platform that delivers clinical trial imaging and biomarker
insights in neurological disease research.

 

The IXI™ 10.0 release brings advances in image reading precision and
analysis, enables larger and faster image data processing, and integrates new
tools for remote image access and data quality qualification.  The latest
generation of IXI™ lays the foundation for IXICO's technology to move beyond
its traditional iCRO remit as part of the Group's TechBio strategy.  The
strategy is focused on increasing IXICO's addressable market by enabling
external organisations to directly access IXICO's technology via licensing,
technology integration and partnering models such as the recently announced
collaboration with Medidata (26 March 2026).

 

About IXI™

Designed by neuroscience and data science experts, the IXI™ Platform is a
proprietary suit of technologies and AI tools tailor-made for neurological
disease complexity.  IXI™ uses machine learning and deep learning to
reliably process data from global trials and build algorithms that precisely
measure key imaging biomarkers associated with the identification, progression
and treatment of Alzheimer's, Parkinson's, Huntington's and other rare
neurological diseases.  It is the only technology platform of its kind
specifically built for, and exclusively focussed on, neuroimaging processing
and neurological biomarker analysis.

 

IXI™ is being used every day across the world. With over 30 cutting edge
analytics algorithms the Platform integrates standardised high quality image
data capture, image reading, advanced analysis and regulatorily compliant
reporting of clinical data. IXI™ supports the biopharma industry to develop
new medicines and diagnostic measures, informing decisions earlier in the drug
development process via a single end to end platform.

 

Bram Goorden, Chief Executive Officer of IXICO, commented:  "As the field of
CNS is rapidly embracing precision medicine, the players in clinical
development need technologies that deliver faster, more scalable and highly
precise biomarker insights. The latest generation of our AI-driven
technology platform IXI™ hosts some of the most advanced algorithms in
neurodegenerative disease, increases accuracy and processing capacity and
further strengthens data quality oversight, all while simplifying user
interaction and integration in established partner platforms. This all with
one objective in mind : helping biopharma make earlier and better-informed
decisions."

 

Ends

 

For further information please contact:

 

 IXICO plc                                        +44 (0) 20 3763 7499
 Grant Nash, Chief Financial Officer

 James Chandler, Chief Business Officer

 Cavendish Capital Markets Limited                +44 (0) 20 7220 0500

 (Nominated Adviser and Sole Broker)
 Giles Balleny, Isaac Hooper (Corporate Finance)

 Nigel Birks (Healthcare Specialist Sales)

 Harriet Ward (Corporate Broking)

 Michael F Johnson (Sales)

 

 

About IXICO www.IXICO.com (http://www.IXICO.com)

IXICO is a global leader in neuroscience imaging and biomarker analytics,
using its proprietary AI-driven platform to help advance the treatment of
neurological disorders and reduce the uncertainties associated with drug
discovery, development and monitoring.   As a key part of the global
neurological disease research community, the Company has built a global
reputation and 20-year track record as an end-to-end Imaging Contract Research
Organisation (iCRO) working with leading pharma companies, innovative
biotechs, disease consortia and non-profit organisations. IXICO has supported
hundreds of neurological clinical trials, analysed hundreds of thousands scans
and built an expansive network of expert imaging centres around the world.

 

The IXI(TM) Platform is tailor-made for neurological disease, reliably
processing data from global trials, precisely measuring key imaging biomarkers
associated with the identification, progression and treatment of diseases such
as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by
the Platform and IXICO's expert scientists translating complex data into
clinically meaningful while minimizing data variability and increasing
reproducibility.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PRLDZGMKRMMGVZG



            Copyright 2019 Regulatory News Service, all rights reserved